Massachusetts General Hospital (MGH) researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.
The method involves a combination of drug therapy to expand the number of targets on tumor cells, and an engineering approach to help the therapy adhere more tightly and durably to those targets.